Updates are available Correction dated 2022-11-28
Click to view Correction: https://doi.org/10.1186/s12940-022-00916-1
-
Authors
Prunicki, Mary
Cauwenberghs, Nicholas
Ataam, Jennifer Arthur
Movassagh, Hesam
Kim, Juyong Brian
Kuznetsova, Tatiana
Wu, Joseph C.
Maecker, Holden
Haddad, Francois
Nadeau, Kari https://orcid.org/0000-0002-2146-2955
-
Funding
Funding for this research was provided by:
National Institutes of Health (NIEHS R01ES02092)
National Institutes of Health (NIEHS R01ES020926)
National Institutes of Health (3R01ES020926)
NIH (NHLBI R01HL081521)
School of Medicine, Stanford University (Sean Parker Center for Allergy and Asthma Research)
- License Information
-
More Information
Article History
Received: 9 April 2020
Accepted: 1 October 2020
First Online: 16 October 2020
Change Date: 28 November 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12940-022-00916-1
Ethics approval and consent to participate
: All participants gave written informed consent for the protocol that was approved by Stanford University’s Institutional Review Board.
: Not applicable.
: Kari Nadeau, MD, PhD: Nadeau reports grants from National Institute of Allergy and Infectious Diseases (NIAID), Food Allergy Research & Education (FARE), End Allergies Together (EAT), Allergenis, and Ukko Pharma; Grant awardee at NIAID, National Institute of Environmental Health Sciences (NIEHS), National Heart, Lung, and Blood Institute (NHLBI), and the Environmental Protection Agency (EPA); Involved in Clinical trials with Regeneron, Genentech, AImmune Therapeutics, DBV Technologies, AnaptysBio, Adare Pharmaceuticals, and Stallergenes-Greer; Research Sponsorship by Novartis, Sanofi, Astellas, Nestle; Data and Safety Monitoring Board member at Novartis and NHLBI; Cofounded BeforeBrands, Alladapt, ForTra, and Iggenix; Director of FARE and World Health Organization (WAO) Center of Excellence; Personal fees from Regeneron, Astrazeneca, ImmuneWorks, and Cour Pharmaceuticals. All other authors declare they have no actual or potential competing financial interests.
